CYP27B1 Inhibitors
1 drugsAbout CYP27B1
CYP27B1 is an enzyme crucial for vitamin D metabolism, catalyzing the conversion of 25-hydroxyvitamin D3 into its active form, 1,25-dihydroxyvitamin D3 (calcitriol). This activation is essential for calcium homeostasis, bone health, and immune function.
CYP27B1 is a therapeutic target for conditions with impaired vitamin D activation. Currently, there is no genetic evidence available linking CYP27B1 to specific diseases.
CYP27B1 is targeted by one FDA-approved small molecule drug, RAYALDEE (EIRGEN), indicated for two conditions. EIRGEN is the only company with an approved drug for this target.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Critically Ill with only 1 trials.
Top CYP27B1 Drugs
EIRGEN is the only company with an approved drug targeting CYP27B1.
The lack of competition suggests a high barrier to entry or an unvalidated market.
CYP27B1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CYP27B1, using small molecule modality.
Exploring alternative modalities like biologics could provide a competitive advantage in this space.
CYP27B1 Clinical Trials 11 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 5 | 4 | 1 | 0 | 80% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 5 | 4 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
CYP27B1 Drug Approval Timeline (2016 - 2016)
RAYALDEE was first approved in 2016 and remains the only approved drug.
The absence of recent approvals indicates a potentially saturated market or limited innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (13 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 15 clinical trials targeting CYP27B1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities